SheepMedical implements new business integration with two companies to strengthen marketing functions and business development in preventive care areas

Sheep Medical Co., Ltd.(Headquarters: Chuo-ku, Tokyo, Representative Director Naozumi Matsumoto, hereinafter "SheepMedical" or "the Company") made ConteeCo., Ltd. (hereinafter "Contee") a wholly owned subsidiary to strengthen marketing functions and further develop business in preventive care fields, and Hirotaka Higashi, the president of Contee became the CMO of the Company. We are also announcing the merger of Microbiota Co., Ltd. (hereinafter "Microbiota"), which provides intestinal bacteria testing solutions.


In recent years, advances in medicine have overcome illnesses and continued to extend lifespan, but on the other hand, increasing medical and long-term care costs have become a global issue.

Therefore, due to health management and prevention, enhancement of life support services, evolution of medical and long-term care technology, etc., the health care market with the theme of preventive care is "About the future direction of the next-generation healthcare industry council" of the Ministry of Health and Welfare.

According to the report, the market is expected to expand to 12.5 trillion yen (approx. $114 billion) in 2025. (*)

Since 2017, we have been conducting orthodontic business focusing on the oral field, which is the entrance to the digestive organs, under the mission of "extending healthy life expectancy and enriching our lives". As the second founding phase, we will expand the theme to the entire preventive care and expand to the intestinal area business that is closely related to the oral field as one of the new businesses.

In order to strengthen our marketing function in line with the enhancement of our existing business and new business development, we have acquired Contee and Mr. Higashi, the president of the company, will be newly appointed as the CMO of SheepMedical.

Through the business integration, we will be able to improve our services from the consumer's perspective by utilizing intraoral data in our aligner business, and further promote research on oral and intestinal microflora for the development of our preventive care business. Through these businesses, we will continue to support people around the world in extending their healthy life expectancy and enriching their lives.

Recent Roles: 2015 Deputy General Manager, Media Management Department, DNA Co., Ltd. 2017 Director, Trust Ridge Co., Ltd. 2018 Contee Co., Ltd. Founded 2021 Sheep Medical Co., Ltd. Executive Officer CMO

Comment from Hirotaka Higashi, President of Contee and CMO of SheepMedical

Since its inception, Contee has provided digital marketing know-how to various clients for joint business operations and new business development.

I believe that in the next 10 years, the huge offline market that has yet to be digitized will be digitized and become a huge online market.  The healthcare field, such as preventive care, is one of the few areas where GAFA does not yet have control of big data, and it is also an area where we can utilize the data of the Japanese people, who have longevity and good health worldwide.

SheepMedical makes products that incorporate specialized medical knowledge into everyday life. By combining Contee's know-how and SheepMedical's assets, we believe that we can provide various solutions for more people.

Company name: CONTEE Co., Ltd. /Contee, Inc.
Representative: Hirotaka Higashi
Established: June 15, 2018
Location: 1-5 Uguisudani-cho, Shibuya-ku, Tokyo
Business description: Digital marketing business service
Website: https: //

Microbiota’s Intestinal bacteria test solution

The intestinal DNA test quantifies the type and ratio of intestinal bacteria, intestinal age, fatness, type determination, and recent diversity through stool tests, and scores dietary habits through questionnaires, enabling people to understand the condition of their intestines, which they did not know before, and to prepare for pre-diseases.

Synergy with SheepMedical
Recent studies have suggested that changes in the intestinal microflora caused by periodontal bacteria are associated with systemic diseases such as atherosclerosis, diabetes, rheumatoid arthritis, non-alcoholic fatty liver disease, and obesity.

We believe that the study of various bacterial flora will lead to important preventive care solutions to improve people's immunity.

By combining Microbiota's thousands of intestinal DNA test data with the tens of thousands of oral condition data from our existing dental business, we aim to contribute to the latest medical treatments in preventive care.

Companyname: Microbiota Co., Ltd.
Representative: Kazunori Shimada
Established: April 17, 2018
Location: 1-1-40 Suehiro-cho, Tsurumi-ku, Yokohama-shi, Kanagawa Yokohama City
Industry-Academia Collaborative Research Center Room 207
Business: Gut microbiota test research, disease diagnosis